16 September 2026 editorial review · Trial
Anti-IL-21 plus liraglutide in recent-onset T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Added historical trial from the current registry and primary publication; distinguished enrollment/analysis populations, study endpoints, benefit limits and program status. Of 308 randomized participants, 307 received treatment and entered the full analysis and safety sets. C-peptide declined by 10% with combination treatment versus 39% with placebo at week 54 (estimated treatment ratio 1.48, 95% CI 1.16–1.89; P=0.0017). Monotherapy comparisons were not significant. Effects diminished after treatment stopped.
Sources: A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function; Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial; Novo Nordisk financial results for the first nine months of 2020.
Limits: Editorial source comparison, not independent clinical certification. A completed trial is not a currently recruiting option.